U.S. markets open in 3 hours 25 minutes

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
265.67-0.76 (-0.29%)
At close: 4:00PM EST
Sign in to post a message.
  • D
    Denis
    Do not buy Abiomed stock before seeing this video!📈 ABMD Stock Analysis. https://www.youtube.com/watch?v=Gb_34GWdKdI
    Do not buy Abiomed stock before seeing this video!📈 ABMD Stock Analysis.
    www.youtube.com
    Bullish
  • G
    Giovanni
    Results are good (exteremely good considering all the surgery delays due to pandemic). The only metrics worsened are expenses, but there was Breethe acquisition to be considered. So after manipulation, this will go back to 300+
    Bullish
  • T
    Tommy
    Question for you Guys. I read somewhere that 19 RCT have already been performed (i mean should be performed!). Each time RCT has failed because of the enrollment (ethical dilema). There is only one ongoing/active RCT ("DANGER"), after 5 years there are only 100 Patient enrolled. We all now know that ABMD is going for CLASS 1 recommondation and will start there own RCTs: PROTECT IV and so on...

    How will ABMD do this? ABMD surely wants to finish it quickly but how? Nobody has done it.
    THANKS
  • G
    Giovanni
    The more I read the results report, the more I think they are excellent! Missing something? Someone would explain to me? I just see manipulation in this drop.
    Bullish
  • B
    Barry
    I couldn’t agree more @Giovanni seems like a major overreaction imo.. what more could you ask of that earnings report
    Bullish
  • M
    Mikous
    Geez, I almost ant to buy it here, but not going to... I'll come back in around 220
  • P
    Presifdsdsf
    10% drop
  • T
    Tommy
    How mich overvalued is this stock? I think for atleast $100 here.
    Max. Growth is 10% for next years so a PE of just >100 is ok?
  • Y
    Yooha
    Would it be a good time to add some shares now?
  • T
    Thomas
    ABMD recently attained the FDA’s Emergency Use Authorization for treating COVID-19-related right heart failure or decompensation, including pulmonary embolism. Also, this might be a help in providing wide range CBD products for medicinal market. See the good news here: https://shr.link/NextMultiBillionIndustryPotential
    One huge segment of the growing $11 trillion-dollar healthcare market is medical devices and equipment. Medical devices can redefine how patients take car..
    One huge segment of the growing $11 trillion-dollar healthcare market is medical devices and equipment. Medical devices can redefine how patients take car..
    shr.link
    Bullish
  • B
    Binaya
    We, in the medical field use Impella all the time. No other device comes close to supporting an acutely injured heart. Usage in cardiac ICU an OR is increasing. Just a matter of time with new trial results earnings and stock will rise back to previous highs.
    Bullish
  • z
    zeus
    So unpredictable for a stock rated strong buy. Hard to believe this was trading 450 6 months ago
    Bearish
  • J
    JAD
    I believe there are also study results that show Impella much more favorable for patient outcomes than Balloon. Part of the problem possibly is proficiency of Users to deliver Impella correctly.
    But you are correct. Sale growth has slowed slightly. They have missed slightly on last 2 QTRs.
    The stock was arguably overpriced at $450. But sure seems to be oversold @ $165.
    Next QTR results are Key. Impella 5.5 may be a plus in guidance because that is coming online now or soon and has great potential
    Bullish
  • P
    Presifdsdsf
    FYI TO ALL. THE MAJOR DROP IN THE LAST WEEK IS DUE TO THE SHIFT IN MARKET RISKS AND RETURNS. HEDGE FUNDS ARE FAVORING MUCH HIGHER GROWTH COMPANIES LIKE MDB ZS AND OKTA VS SLOW GROWTH MED DEVICE INDUSTRY COMPANIES.
  • A
    Adrienne
    I’ve never seen a stock with solid fundamental (FDA approvals, respectable growth profile, sound financials) move like a broken stock... until ABMD. I am still averaging down. Gone this far with this stock (since 290s). I hope one of the bigger boys like Medtronic will acquire it. I dont see other way out. It has fallen despite every positive headlines.
    Bullish
  • J
    Jules
    Shorts are very stubborn on this stock. They have been trying to get it to $150 since the big drop months ago. The low daily average volume allows them to just kick back and control the trading price. This stock has made multiple failed attempts to get in the $200 range but every time it has some momentum, a re-print short article pops up to scare new buyers and attract more shorts. This stock just drip under $155 for the shorts to cover and move on.or big buyers on the ask for a few days keeps this over $225 and force them to cover.
    For now, it's a tight range between $175 and $196 until something changes it.
  • B
    Bill
    got back in and added a few shares at 250. I have been trading this stock for about 4 yrs. solid company that will work it way back up to $400. they have little competition and are at the top of their game.
  • T
    Todd
    I have owned shares of Abiomed at $18 and bought as high as $369 and back down to its current range of $176-$178. It has been painful to watch the stock fall from highs of $450; of course in hindsight I wish to have sold more shares on the way down. My optimism for buying on the way up was the product itself, Impella is one of the most innovative and significant devices in the Cardiovascular/Heart failure space today. I still feel the same about the device, but at these levels and a market cap around 8B Abiomed now presents itself as a viable buyout . At a 14-16B price tag Abiomed could be an attractive and very doable takeover for companies such as Abbott, who is building their Heart Failure space (acquisition of St Jude) or Phillips, who would benefit from integration of the Impella hardware in their cath lab systems (similar reason Siemens recently bought Corindus Vascular Robotics). In addition, Abiomed who be a great fit for Boston Scientific or Medtronic providing relevance to their coronary portfolios. Bottom line, if Abiomed continues to falter and management can not provide any confidence to the market and soon a buyout will be in their future.
    Bullish
  • V
    Vik
    From ZACK April 9, 19
    ABIOMED, Inc.engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings increased 3.7% over the past 60 days. The company’s expected earnings growth rate for the current year is 106.1%, higher than the Medical - Instruments industry’s rise of 17.7%. The company has outperformed the broader industry in the past two-year period (+127.7% vs +37.4%).
    Bullish
  • P
    Presifdsdsf
    Ok. We know now what happened. Revenue growth has slowed greatly. But guidance is ok